Intriguingly, it has been reported that PI3K/AKT signaling pathway is identified as a crucial regulator of proliferation and survival of tumor cells in DLBCL, and therefore targeting the signaling might be a promising therapeutic intervention for DLBCL patients [34, 35]. Here, AKT1 is linked to diffuse large B-cell lymphoma.